Pittenger & Anderson Inc. Buys 8,669 Shares of Edwards Lifesciences Corporation $EW

Pittenger & Anderson Inc. lifted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 49.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,186 shares of the medical research company’s stock after purchasing an additional 8,669 shares during the period. Pittenger & Anderson Inc.’s holdings in Edwards Lifesciences were worth $2,097,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. MV Capital Management Inc. purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at $26,000. Hanson & Doremus Investment Management bought a new position in shares of Edwards Lifesciences during the 1st quarter worth $25,000. Kemnay Advisory Services Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter worth about $27,000. JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter worth about $25,000. Finally, Hilton Head Capital Partners LLC bought a new stake in Edwards Lifesciences in the 4th quarter valued at about $28,000. Institutional investors own 79.46% of the company’s stock.

Insider Activity

In other news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares of the company’s stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 45,577 shares of company stock worth $3,855,527. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Price Performance

Shares of EW traded up $0.89 during mid-day trading on Friday, reaching $92.22. 3,381,397 shares of the stock traded hands, compared to its average volume of 4,354,287. The company has a market cap of $53.10 billion, a price-to-earnings ratio of 49.05, a price-to-earnings-growth ratio of 2.31 and a beta of 0.86. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29. The firm has a fifty day moving average price of $86.73 and a 200 day moving average price of $83.87. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same quarter last year, the business posted $0.64 earnings per share. The firm’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on EW shares. Royal Bank Of Canada restated an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a research note on Tuesday, June 16th. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective on the stock in a research note on Wednesday, April 1st. Citigroup increased their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday. BTIG Research raised their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Finally, Evercore reaffirmed an “outperform” rating and set a $100.00 target price on shares of Edwards Lifesciences in a report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.09.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.